Novel Phosphodiesterase Type 5 Inhibitors: Assessing Hemodynamic Effects and Safety Parameters

Clinical Cardiology

Volumn 27, Issue 4 SUPPL., 2004, Pages

  Kloner, Robert A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

Hemodynamic effects; Ischemia; Myocardial infarction; Nitrates; Phosphodiesterase type 5 inhibitors; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; GLYCERYL TRINITRATE; NIFEDIPINE; NITRATE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT; VARDENAFIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; EXERCISE TEST; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART RATE; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPOTENSION; MALE; PARAMETER; STABLE ANGINA PECTORIS; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TREATMENT CONTRAINDICATION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 1842532513     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960271306     Document Type: Conference Paper

References (25)

1. Zusman RM, Morales A, Glasser DB, Osterloh IH: Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83:35C-44C
2. Cialis® (tadalafil) (package insert). Indianapolis, Ind. and Bothell, Wash.: LilIy ICOS LLC; 2003.
3. Emmick JT, Stuewe SR, Mitchell M: Overview of the cardiovascular effects of tadalafil. Eur Heart J Suppl 2002;4(suppl H): H32-H47
4. Kloner RA, Mitchell M, Emmick JT: Cardiovascular effects of tadalafil. Am J Cardiol 2003;92(suppl):37M-46M
5. Stark S, Sachse R, Liedl T, Hensen J, Rohde G, Wensing G, Horstmann R, Schrott KM: Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001;40:181-190
6. Jackson G, Betteridge J, Dean J, Hall R, Holdright D, Holmes S, Kirby M, Riley A, Sever P: A systematic approach to erectile dysfunction in the cardiovascular patient: A consensus statement. Int J Clin Pract 1999;53:445-451
7. Kloner RA, Mitchell MI, Bedding A, Emmick J: Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil (abstr 708). J Urol 2002;167(suppl):176-177
8. Kloner RA, Emmick J, Bedding A, Humen D: Pharmacodynamic interactions between tadalafil and nitrates (abstr 291A). J Am Coll Cardiol 2002;39(suppl A)
9. Levitra® (vardenafil) (package insert). West Haven, Conn: Bayer Pharmaceuticals Corp., 2003
10. Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G: Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42:1855-1860
11. Padma-Nathan H, Eardley I, Kloner RA, Lalies AM, Montorsi F: A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002;60(suppl 2B):67-90
12. Viagra® (sildenafil) (package insert). New York, NY: Pfizer Inc., 2003
13. Arruda-Olson A, Mahoney DW, Nehra A, Leckel M, Pellikka PA: Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. A randomized crossover trial. J Am Med Assoc 2002;287:719-725
14. Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P, Stein RA, Larkin S, Mazzu A, Tota R, Pomerantz K, Sundaresan P: The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002;40:2006-2012
15. Patterson D, MacDonald TM, Effron MB, Emmick JT, Mitchell MI, Kloner RA: Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease (abstr 1650). Circulation 2002;106(suppl):330
16. Boshier A, Wilton LV, Shakir SAW: Cardiovascular events in a cohort study of sildenafil users in England. Poster presented at 5th Congress of the European Society for Sexual and Impotence Research, Hamburg, Germany, December 1-4, 2002
17. Sadovsky R, Miller T, Moskowitz M: Three-year update of sildenafil citrate (Viagra®) efficacy and safety. Int J Clin Pract 2001;55:115-128
18. Alpaslan M, Onrat E, Smldi M, Dincel C: Sildenafil citrate does not affect QT intervals and QT dispersion: An important observation for drug safety. Ann Noninvas Electrocardiol 2003;8:14-17
19. Sofowora G, Dishy V, Roden D, Wood AJJ, Stein CM: The effect of sildenafil on QT interval in healthy men (abstr PIII-II). Clin Pharmacol Ther 2001;69:P67
20. Data on file. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee: Levitra® tablets. Available at: http://www.fda.gov/ohrms/dockets/ac/03/slides/3956S1_03_Bayer.ppt. Accessed September 5, 2003
21. Kloner RA, Mitchell M, Emmick JT: Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003; 92(suppl):47M-57M
22. Webb DJ, Freestone S, Allen MJ, Muirhead GJ: Sildenafil citrate and blood pressure-lowering drogs: Results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999;83:21C-28C
23. Kloner RA, Brown M, Prisant LM, Collins M: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 2001;14:70-73
24. Rohde G, Jordaan PJ: Influence of vardenafil on blood pressure and pharmacokinetics in hypertensive patients on nifedipine therapy (abstr). Pharmacotherapy 2002;22:418
25. Padma-Nathan H, Porst H, Eardley T, Thibonnier M: Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy (abstr). Am J Hypertens 2002;15(suppl):48A